> Mein DÄ

POLITIK: Medizinreport

Onkologie: Highlights einer Großveranstaltung

Dtsch Arztebl 2002; 99(42): A-2755 / B-2348 / C-2203

Junker, Annette

1.	STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabin as initial therapy for patients with CML: results of a randomized study. BJ Druker, for the IRIS (International Randomized IFN vs. STI571) Study Group; Oregon Health & Science University, Portland, OR. ASCO 2002, abstr. 1.
2.	High incidence of durable responses induced by Imatinib Mesylate (GleevecTM) in patients with unresectable and metastatic gastrointestinal stroma tumors (GISTs). Margaret von Mehren, Fox Chase Cancer Ctr., Philadelphia, PA; Charles Blanke, OHSU, Portland, OR; Heikki Joensuu, University Hospital, Helsinki Finland; Mike Heinrich, OHSU, Portland, OR; Peter Roberts, University Hospital, Helsinki Finland; Burton Eisenberg, Fox Chase Cancer Ctr, Philadelphia, PA; Sandra Silberman, Novartis Oncology, East Hanover, NJ; Sasa Dimitrijevic, Beate Kiese, Novartis Oncology, Basel Switzerland; Jonathan Fletcher, Christopher Fletcher, George Demetri, Dana-Farber Cancer Institute, Boston, MA. ASCO 2002, abstr. 1608.
3.	N9741: oxaliplatin (oxal) or CPT-11+5-fluorouracil (5FU)/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. RM Goldberg, RF Morton, DJ Sargent, CS Fuchs, RK Ramanathan, SK Williamson, BP Findlay; Mayo Clinic, Rochester, MN; NCCTG, Des Moines, IA; CALGB, Boston, MA; ECOG, Pittsburgh, PA; SWOG, Kansas City, KS; NCIC, St. Catharines, Canada. ASCO 2002, abstr 511.
4.	PSA Testing Interval Reduction in Screening Intervals: Data from the Prostata, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. E.D. Crawford, Univ of Colorado Health Sciences Ctr., Denver, CO; David Chia PhD, University of California at Los Angeles, Los Angeles, CA; Gerld L Andriole MD, Washington University School of Medicine, St. Louis, MO; Douglas Redding, Marshfield Clinic and Medical Center, Marshfield, WI; Edward P Gelmann, Georgetown University Medical Center, Washington, DC; John K Gohagan, Paul Pinsky, Richard B Hayes, David L Levin, Richard M Fagerstrom, NCI, Dividion of Cancer Prevention, Bethesda, MD; Barnett S Kramer, NIH/NCI, Office of Medical Applications of Research, Bethesda, MD. ASCO 2002, abstr. 4.
5.	Baum M et al.: The ATAC (Arimidex, Tamoxifen Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Br Cancer Res Treat 2001; 69 (3): abstract 8.

Zum Artikel

Login

Passwort vergessen?

Registrieren

Eingeloggt als $LOGINEMAIL$